# Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

> **NCT05963217** · PHASE1 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 19 (estimated)

## Conditions studied

- Relapsed or Refractory CD19+ B-cell Lymphoma
- Relapsed or Refractory Chronic Lymphocytic Leukemia
- Relapsed or Refractory Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** TBI-2001
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT05963217
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-26
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05963217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05963217, "Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05963217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*